Abstract: This study examines the treatment-outcome and treatment-cost relationships for Acute Myocardial Infarction (AMI) in Taiwan, where National Health Insurance (NHI) was adopted in 1995. We assessed usage trends in technologically advanced procedural treatments for 31,226 AMI patients 170 W. Yip et al. from 1997Yip et al. from to 2001, isolated the effects of changes in treatment usage on mortality and medical spending, and compared the values of estimated life-gains to their associated cost increases. Taiwan's experience suggests that by providing comprehensive coverage and by controlling provider prices, NHI was able to improve population-level health by making available technologically advanced procedural treatments while at the same time managing the inflationary pressures associated with these innovations.
Introduction
The debate over universal healthcare generally reveals two competing priorities: 1 to ameliorate the plight of the under-insured, under-privileged, or under-resourced members of society 2 to effectively manage rising medical costs.
While several studies have shown that the uninsured suffer with respect to medical access and health outcomes relative to their insured counterparts, implying that universal healthcare delivers with respect to priority (1), the literature has produced little by way of systematic evidence as to the relationship between universal healthcare and cost inflation, implying that priority (1) may or may not be in conflict with priority (2). By and large, however, this debate has privileged ideology above evidence. Underlying such a discourse is a common challenge facing health policymakers around the world: how to improve medical access and health outcomes while simultaneously controlling medical spending (Cutler, 2002) , a conflict that becomes more pronounced when new medical technologies emerge. Advanced technological treatments have the potential to bring about measurable improvements in health outcomes, but they are also positively associated with increasing medical costs (Cutler and McClellan, 1998; Newhouse, 1992; Weisbrod, 1991) . In fact, much of the economics literature in the USA subscribes to the view that technological innovation is one of the primary cost drivers in the healthcare industry (Aaron and Schwartz, 1984; Altman and Blendon, 1977; Cutler and McClellan, 1998; Hay, 2003; Koenig et al., 2003; LaCronique and Sandier, 1981; The Lewin Group, 2002; Newhouse, 1992; Showstack et al., 1982; Weisbrod, 1991; Wilensky, 1990) . Are the health improvements associated with new technologies necessarily cost inflationary? And can health systems be structured in such a way as to moderate inflationary pressures without compromising on these health improvements?
We addressed these questions by examining Taiwan's National Health Insurance (NHI) program. Established in March 1995, NHI provides universal and comprehensive insurance to all Taiwanese residents. It covers inpatient hospitalisations, outpatient services, prescription drugs, Chinese medicine, dental care, and home visits. As a single purchaser, the Bureau of NHI (BNHI) has contracts with over 97% of the providers in Taiwan and reimburses them based on a fixed-fee schedule. NHI beneficiaries have complete freedom of choice in providers, with low to moderate cost-sharing.
We analysed patterns in technologically advanced procedural treatment usage, health outcomes, and costs for Taiwanese patients who suffered Acute Myocardial Infarction (AMI). We focused on AMI for several reasons. First, as in many countries, cardiovascular disease is one of the leading causes of death in Taiwan. Second, coronary artery disease patients have benefited from major technological innovations that have proven effective in improving health outcomes, but which are also relatively expensive. Focusing on AMI allows us to investigate the trade-off between improving medical access and health outcomes and managing costs as new technologies are adopted. Third, AMI cases are statistically unambiguous events that allow us to accurately and reliably pinpoint the time of onset. Fourth, given the seriousness of AMI, we may clearly and objectively measure health outcomes as mortality rates following a heart attack.
Methods

Data
The primary data were derived from NHI inpatient claims between 1997 and 2001. Although NHI was established in 1995, data for 1995 and 1996 were unreliable and incomplete, which may have been attributable to errors in recordkeeping and data collection under the new system. The year 2001 provided the last available data at the time this study was conducted. The claims data were similar to American hospital discharge data, or to inpatient claims files for Medicare beneficiaries in the USA. However, as a single insurer, the BNHI compiled records for nearly all recipients of medical care in Taiwan during these years. The claims provided basic demographic information, dates of hospital admission and discharge, diagnosis and procedural codes, and expenditure amounts.
To define a sample of new AMI admissions, we followed methods previously established in the literature (Lo and Lai, 2002) . All claims between 1997 and 2001 with a primary diagnosis of AMI (ICD-9-CM code 410) were extracted. To limit the sample to initial AMI admissions, we excluded the following people: patients with ICD-9-CM code 410.02, which indicated subsequent episodes, or follow-up care for previous AMI admissions; patients discharged alive, and not transferred, within three days or less following inpatient admission, assuming that these observations represented miscoded or rule-out rather than true AMI cases; and patients admitted for AMI within one year of the present admission, to ensure that our sample included only new AMI cases.
The inpatient claims were linked to the Department of Health (DoH) death certificate records, which provided the dates and underlying causes of death. The sample subsequently was restricted to patients older than 30 and younger than 85 years of age. Patients of 85 years and older were excluded because death records before 1,911 were incomplete, which may have led to an underestimation of mortality rates for patients of 85 years and older in 1997 if included. Since only a small proportion of the overall sample was less than 30 years of age, we excluded these observations as well. A sensitivity analysis indicated that the results were robust to these age restrictions. The final sample consisted of 31,226 AMI patients between 1997 and 2001, each of whom was assigned to a yearly cohort based on her date of hospital discharge.
Analysis
Trends in usage for advanced technologies were constructed by estimating the share of patients in each yearly cohort receiving the following treatments: medical management, catheterisation only (ICD-9-CM codes 8853-7, 3722, 3723), Percutaneous Transluminal Coronary Angioplasty (PTCA) (ICD-9-CM codes 3601, 3602 and 3605), and Coronary Artery Bypass Graft surgery (CABG) (ICD-9-CM codes 361 and 3603). We excluded 96 patients (0.3% of the sample) who received both PTCA and CABG, a subgroup that may have represented a confounding case-mix. Health outcomes were captured by mortality rates, which were adjusted to the demographic and case-mix distribution for the 1997 cohort. Demographics were captured by age and sex, and case-mix was captured by the Charlson Index (Charlson et al., 1987; Romano et al., 1993) . Since there were no direct cost data, we estimated costs using total medical spending per patient, which included expenditures on the initial inpatient hospitalisations as well as any medical spending incurred within one year of those admissions. Expenditures were made under NHI and by patients themselves in the form of co-payments. All figures in this paper are given in 1997 US dollars.
We analysed the extent to which changes in usage shares for advanced technological treatments contributed to changes in mortality rates by decomposing the changes in mortality rates into changes in treatment-specific mortality rates and changes in treatment usage shares. We then analysed the extent to which changes in usage shares for advanced technological treatments contributed to changes in medical spending by decomposing the changes in medical spending into changes in treatment-specific prices and changes in treatment usage shares. Finally, we performed a cost-benefit analysis to compare the changes in the value of life to the changes in treatment expenditure on average. Although there is no general consensus as to the definition of health benefit or reduction, we measured benefit/reduction as the value of life-years gained/lost as a result of changes in mortality rates. To facilitate comparison, we followed closely the methodology applied in previous US studies (Cutler and Huckman, 2003; Cutler and McClellan, 1998; McClellan and Kessler, 2002; Technological Change in Healthcare Research Network, 2001 ). Using Taiwanese life tables from the Ministry of Interior (MoI), we first estimated life expectancies conditional upon having survived a heart attack for each year of our five-year period. Given predicted changes in life expectancies, we then estimated changes in expected future life-years discounted to the present at a rate of 3%. We valued these changes at $25,000 per life-year, a value twice the magnitude of Taiwanese per-capita GDP.
Results
Sample characteristics
As shown in Table 1 , the average patient was about 65 years of age, and approximately 57.2% of the sample was elderly, classified here as 65 years of age or older. Close to three quarters of the AMI patients were male. Case-mix co-morbidity, captured by the Charlson Index, increased over time. This increase may reflect a real increase in illness severity or upcoding. The share of the population admitted as inpatients for AMI increased between 1997 and 2001 by 2.3% per year on average, 2.5% per year for men and 2.2% per year for women. This increase suggests that, over time, either a larger share of the population suffered AMI, or that a larger share of the population suffering from AMI sought treatment, although the latter is less likely. Because of the severity of AMI, it is unlikely that many patients who suffered a true heart attack were not admitted to a hospital, unless of course the events were fatal.
Female AMI patients tended to be older and sicker than their male counterparts. The share of elderly female patients was approximately 18 percentage points higher than the share of elderly male patients. Female patients also had a higher degree of co-morbid health impairments, partly because they were older. However, the data also showed that heart attack incidence for men was more than 2.7 times that of women. These findings may be due to physiological differences between men and women, where men were more biologically prone to develop heart disease and suffer heart attacks, especially at a younger and healthier stage of life. Alternatively, behavioural differences in treatment-seeking may be attributable to a culture that perceived cardiovascular health risk as a male concern and downplayed the significance of female symptoms, leading to the inpatient hospitalisation of females who were older and in worse health than they would have been otherwise. However, the investigation of these sex differences is beyond the scope of this paper. † For each AMI patient, the Charlson Index is a weighted sum of co-morbid health conditions. Old myocardial infarction, peripheral vascular disease, dementia, chronic pulmonary disease, rheumatologic disease, mild liver disease, and mild to moderate diabetes are each given one point; diabetes with chronic complications, renal disease, and any malignancy (including lymphoma and leukaemia) are each given two points; moderate to severe liver disease is given three points; and metastatic solid tumour is given six points. ‡ We estimated incidence using mid-year population counts for people older than 30 and younger than 85 years of age.
Trends in treatment
As shown in the upper panel of Table 2 , treatment patterns changed significantly between 1997 and 2001. There was a major shift away from medical management and towards invasive procedures. In particular, there was a significant increase in the share of patients undergoing PTCA, from 17.8% to 31.7%. While the share of patients undergoing CABG also increased from 1.7% to 2.2%, the share itself remained low. 
Trends in outcomes and the treatment-outcome relationship
Adjusted mortality rates were calculated at 1 day, 90 days, and 1-5 years post-AMI for the 1997, 1999 and 2001 cohorts (see Figure 1 ). As shown in the middle panel of Table 2 , conditional upon having survived a heart attack, the cumulative mortality rate one year later was about 27.4% for the 1997 cohort. This figure dropped to 25.6% for the 1999 cohort and 24.3% for the 2001 cohort. These results indicate that overall mortality rates fell by about 0.8 percentage points per year between 1997 and 2001. One-year AMI mortality improved over time across all ages and both sexes fairly equally, yet the reduction was slightly more pronounced for the non-elderly (fell by 0.9 percentage points per year) than for the elderly (fell by 0.7 percentage points per year). How much of this reduction in mortality can be explained by changes in treatment patterns vs. other factors? As illustrated in the upper and middle panels of Table 2 , there were major changes in treatment patterns. Yet the reductions in treatment-specific mortality rates were small relative to the reduction in overall mortality rates. The results from the decomposition (Table 3) showed that around 88% of the total mortality reduction was attributable to increases in the shares of usage for technologically advanced treatments, while 10% was attributable to treatment-specific mortality reductions, which may themselves be related to further technological improvements or better performance by physicians due to accumulated experience. The percentages do not sum to 100 because increases in the shares of usage for technologically advanced treatments and treatment-specific mortality reductions were positively correlated, as evidenced by the positive relationship highlighted in the outcome-volume literature (Luft et al., 1979; Ho, 2000) . 
Trends in costs and the treatment-cost relationship
As shown in the lower panel of Table 2 , between 1997 and 2001 real medical spending per AMI patient increased by $635, from $4,527 to $5,162, or 3.3% annually. However, except for basic medical management, real per-capita spending actually decreased.
This suggests that the increase in total per-capita cost was largely driven by the increased share of patients receiving advanced treatments that are more expensive such as PTCA and CABG. How much of the increase in expenditure was explained by increases in the shares of treatment usage vs. changes in the treatment-specific unit prices? The results from the decomposition (Table 4) showed that approximately 31.1% of the increase in expenditure attributable to increases in treatment-specific unit prices, while 105.2% was attributable to changes in shares of usage. 
Comparison to the USA
How does Taiwan's experience compare with that of the USA? How did treatment patterns differ? To what relative degree was Taiwan able to achieve health improvements through an increased use of advanced technological procedural treatments while at the same time managing the growth in spending? Both countries experienced major shifts in treatment towards advanced technologies and away from medical management. However, there was one striking difference. In the USA, the PTCA rate increased from about 1% to about 17%, and the CABG rate increased from about 5% to about 15% for elderly Medicare patients between 1984 and 1994 . In Taiwan, the overall increase was sizeable for PTCA, while CABG rates remained relatively low after a slight increase. Although the time periods and demographic characteristics do not allow for a direct comparison, these statistics highlight some of the major differences in usage for advanced technological procedural treatments between the two countries.
We estimated that the reduction in AMI mortality achieved between 1997 and 2001 in Taiwan translated into life-gains worth $31,979, a figure much higher than the cost increase of $635 (see Table 5 ). If we restrict our sample to the elderly over the same period, the gain was $17,491 of life at a cost increase of only $835, giving a cost-benefit ratio of 0.0477. Between 1984 and 1994, elderly AMI patients in the USA gained $24,397 of life at a cost increase of $7,548, giving a cost-benefit ratio of 0.3094 ). The American cost-benefit ratio is more than six times that of the Taiwanese ratio. The comparison between the USA and Taiwan is not ideal. We compared across different time periods, different technologies, and different cultures. However, the magnitude of the difference suggests that at the very least, Taiwan's experience may provide some insight into the trade-off between the utilisation of expensive medical technology and health expenditure inflation.
Discussion
Our results suggest that Taiwan was able to achieve substantial AMI mortality reductions while successfully managing cost inflation. During the study period, the reduction in mortality was largely attributable to increased use of advanced technological treatments, while per-unit treatment costs were maintained at low levels. What may be the plausible explanation for these results? Since our data do not pre-date NHI, we cannot infer a direct causal link between the NHI and the observed changes in treatments, mortality rates, and medical spending. However, we can deduce certain logical associations. First, we hypothesise that the increased use of advanced technological treatments, as well as the associated reductions in mortality rates, were attributable to universal and comprehensive coverage under NHI. The NHI improved access to care and made available otherwise expensive and unaffordable treatments. As shown in Table 6 , over five years AMI patients became more likely to be admitted to medical centres and to regional hospitals than to local hospitals. In 1997, the shares of AMI patients treated at medical centres, regional hospitals, and local community hospitals were 34.0%, 34.1%, and 31.9%, respectively. In 2001, those shares were 42.4%, 40.3%, and 17.3%, respectively. These trends are substantial and would not have been possible without the NHI. In Taiwan, medical centres and regional hospitals are higher-level facilities that possess the capacities, including staff and equipment, to perform PTCA and CABG. Medical centres and regional hospitals also have larger patient volumes or heavier teaching responsibilities, two factors which generally contribute to better patient outcomes. As shown in the lower panel of Table 6 , not only were mortality rates at medical centres and regional hospitals lower (15.9% lower on average across five years), but also the reduction over time was greater for these facilities. Mortality rates following a heart attack fell by approximately 0.7 and 0.8 percentage points per year for medical centres and regional hospitals, respectively, while mortality rates decreased by about 0.2 percentage points per year for the local community hospitals.
Second, we hypothesise that the methods of payment and the organisation of hospitals and physicians may have allowed Taiwan to manage expenditure growth for AMI cases, despite the rapid increase in use of technologically advanced treatments. As a single purchaser, Taiwan's NHI pays providers according to a fixed-fee schedule. When NHI was established in 1995, the effectiveness of PTCA, in terms of rates of restenosis and mortality, had improved considerably since it was first introduced in the late 1980s (Williams et al., 2000) . To create incentives for providers to select PTCA over the more expensive CABG, the BNHI set a fee schedule that compensated PTCA procedures relatively more generously than CABG procedures. To illustrate, in 1996, the fee for a two-vessel PTCA was $1,715, while that for CABG was only $915. Unlike the USA, Taiwan's NHI pays hospitals rather than physicians. All physicians are employed as hospital staff, and non-staff physicians do not have admitting privileges. Hospitals pass on financial incentives to their physician staff by sharing a fixed percentage of the procedure-specific fees they receive with their physicians. Given that CABG is more difficult and riskier than PTCA, relative price differences provide a major incentive for PTCA above CABG. In addition, as a single payer with one payment method and one payment rate, the NHI can also effectively control system-level cost by avoiding cost-shifting, a problem that often plagues systems with multiple payers, as in the USA.
There are several limitations for these inferences and conclusions. First, our study focuses on the experience of AMI patients, and it does not address the broader question of whether the increased usage of advanced technological procedures is necessarily cost-increasing in general. To test that, a study would need to examine treatment, outcome, and cost for a comprehensive group of diseases. Second, Taiwan's NHI did not reimburse PTCA with more than two stents until after 2001, which means we have underestimated the actual use of PTCA. Third, in addition to differences in payment incentives as discussed above, the relatively low rates of CABG may be attributable to other factors, which we cannot empirically isolate. For example, by the time Taiwan adopted PTCA and CABG, exogenous technological changes and accumulated knowledge had made PTCA a more attractive option than when it was adopted in the USA in the 1980s (Williams et al., 2000) . Some researchers in Taiwan have suggested that the relatively low ratio of cardiac surgeons to cardiologists places further constraints on the expansion of CABG. What explains the relatively low supply of cardiac surgeons is, however, a separate question.
Despite these limitations, the major change in AMI patients' admission to higher-level facilities, the rapid increase in the use of PTCA, and the large magnitude of difference in the use of CABG between the USA and Taiwan suggest that comprehensive insurance coverage and the use of pricing incentives by the NHI are key contributors to the observed trends. Our results strongly suggest that the ways in which health systems are structured can be important determinants in whether a system can strike a balance between improving access and population health while effectively managing cost.
